PATENT CLAIM ANALYSIS

Application Number: 15754173
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2019-01
Patent Classification: ["514", "006500"]

Abstract:
The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

Claim (Index 21):
The acylated insulin analogue according to  claim 1 , wherein, in the group of Formula II\n [Acyl]-[Linker]- the Acyl group is a residue of an \u03b1,\u03c9-di-carboxylic acid selected from 1,14-tetradecanedioic acid; 1,15-pentadecanedioic acid; and 1,16-hexadecanedioic acid.

Metadata:
- Claim Count in Document: 37.0
- Percentile: 88.0
- Lexical Diversity: 1.63158
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15121206', '14471258', '14616293', '14686176', '12673337']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8343048285292104
- 35 USC 102 Novelty (BERT): 0.6291355594026142
- Combined Prediction Score: 0.8137879016165508
- Mean Citation Score: 494.690622
- Max Citation Score: 651.9261
- Similarity Product: 523.490268208623

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test